Literature DB >> 7685148

Age-related macular degeneration and choroidal neovascularization.

K B Freund1, L A Yannuzzi, J A Sorenson.   

Abstract

The neovascular variant of age-related macular degeneration is amenable to laser photocoagulation treatment within well-defined guidelines established by clinical trials. However, only a limited number of patients meet eligibility criteria for this form of treatment, principally because of the ill-defined, or occult nature, of the choroidal neovascularization commonly seen. Previous studies have estimated that one half of patients with neovascular age-related macular degeneration have occult neovascularization at initial manifestation of the disease. We examined the initial findings of 67 patients with newly diagnosed unilateral neovascular age-related macular degeneration. Eighty-seven percent of these patients (58 of 67) had disease that did not meet Macular Photocoagulation Study Group guidelines for laser photocoagulation treatment. As so few patients are eligible for laser photocoagulation, further research into new techniques of diagnosis and treatment for this disorder is warranted.

Entities:  

Mesh:

Year:  1993        PMID: 7685148     DOI: 10.1016/s0002-9394(14)73649-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  49 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study.

Authors:  G Donati; D Soubrane; M Quaranta; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

3.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

4.  Chorioretinal temperature monitoring during transpupillary thermotherapy for choroidal neovascularisation.

Authors:  S Miura; H Nishiwaki; Y Ieki; Y Hirata; Y Honda; Y Sugino; Y Okazaki
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

5.  Improved visualisation of choroidal neovascularisation by scanning laser ophthalmoscope using image averaging.

Authors:  D U Bartsch; M H El-Bradey; A El-Musharaf; W R Freeman
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

6.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

7.  Clinicopathological correlation of primary and recurrent choroidal neovascularisation following surgical excision in age related macular degeneration.

Authors:  A A Castellarin; M A Nasir; I K Sugino; M A Zarbin
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

Review 8.  Alternative therapies in exudative age related macular degeneration.

Authors:  N H Chong; A C Bird
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

9.  Strontium plaque irradiation of subfoveal neovascular membranes in age-related macular degeneration.

Authors:  A Jaakkola; J Heikkonen; P Tommila; L Laatikainen; I Immonen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-01       Impact factor: 3.117

10.  Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Authors:  Md Jashim Uddin; Chauca E Moore; Brenda C Crews; Cristina K Daniel; Kebreab Ghebreselasie; J Oliver McIntyre; Lawrence J Marnett; Ashwath Jayagopal
Journal:  J Biomed Opt       Date:  2016-09-01       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.